The Diagnostic Application of PSMAPET/MR in Patients Undergoing Secondary Prostate Puncture

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Mar 23, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how effective a specialized imaging technique called PSMA PET/CT, along with another method called mpMRI, can be in guiding prostate biopsies for men who have a low PSA level and have had a negative initial biopsy. Essentially, the study aims to see if these imaging methods can help doctors better locate cancer in the prostate when previous tests haven't shown any clear results.

To participate, men must be at least 40 years old and have a PSA level between 4 and 20 ng/mL, which is a common blood test measurement used to check for prostate issues. Participants will also need to be able to safely undergo the imaging procedures and agree to take part in the study by signing a consent form. However, those with a PSA level above 20 ng/mL, certain medical conditions, or previous treatments for prostate cancer will not be eligible. If you join this study, you may experience a targeted biopsy that could help determine if you have prostate cancer more accurately than standard methods.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥40 years, male;
• • 2. Serum PSA level 4-20 ng/mL;
• • 3. Serum PSA level 4-20 ng/mL;
• • 4. No contraindications to PSMA-PET/CT or MRI;
• • 5. Signed informed consent.
• Exclusion Criteria:
• • 1. Serum PSA \>20 ng/mL;
• • 2. History of prostate surgery/radiotherapy;
• • 3. Acute prostatitis;
• • 4. Coagulation disorders or active infection;
• • 5. Severe internal/external hemorrhoids, perianal, rectal, or gluteal lesions;
• • 6. Allergy to local anesthetics;
• • 7. Inability to tolerate the biopsy procedure.